CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 30 target
Drug / intervention
autologous immune cell therapybiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03085966
NCT03085966Phase 2Unknown
CompareCT.gov

Study of Autologous Immune Cell Therapy in Combination With the Luteinizing Hormone Releasing Hormone Agonists (LHRH-a) in Patients With Metastatic Castration-resistant Prostate Cancer

Shanghai AbelZeta Ltd.·interventional·Posted Mar 21, 2017·Updated Mar 21, 2017

In Brief

A Phase 2 clinical trial evaluating autologous immune cell therapy for Metastatic Castration-resistant Prostate Cancer. Targeting 30 participants across 1 site.

Detailed Summary

Study of autologous immune cell therapy in combination with the luteinizing hormone releasing hormone agonists (LHRH-a) in patients with metastatic castration-resistant prostate cancer

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Castration-resistant Prostate Cancer
CountriesChina
CollaboratorsFudan University

Timeline

Phase 2UnknownOverdue
2017201820192020202120222023202420252026
First PostedMar 21, 2017
Enrollment StartFeb 27, 2017
Primary CompletionOct 27, 2019
Study CompletionDec 27, 2019
TodayJul 1, 2026
Enrollment to primary: 2.7 yearsPosted 9.3 years ago

Interventions

autologous immune cell therapybiological

Luteinizing Hormone Releasing Hormone Agonists (LHRH-a) and Autologous dendritic cells (DC) and central memory T cells (Tcm cells)